Incident · Regulatory action
FDA warning letter to Whoop: Blood Pressure Insights marketed beyond clearance
On July 14 2025 the FDA issued Whoop a warning letter (MARCS-CMS 709755) stating that the Blood Pressure Insights (BPI) daily systolic/diastolic estimation feature on the WHOOP MG / Life membership is an unapproved medical device marketed without clearance, since BP estimation is inherently tied to diagnosis of hypo-/hypertension. Whoop publicly disagreed (Jul 15 2025) and BPI remained accessible; as of mid-2026 the dispute is UNRESOLVED with no recall. The load-bearing marketing-beyond-clearance exemplar of the biometric cohort.
Occurred 2025-07-14 · Whoop (5.0 / MG)
Machine-readable surfaces
- Markdown mirror: /incidents/whoop-bpi-fda-warning-letter-2025.md
- JSON-LD: embedded in this page’s head
- REST API: /v1/incidents/2551f142-584e-48a5-978d-ff8c82023c01
- Data documentation: /data
Sources (2)
Common questions
- What happened in FDA warning letter to Whoop: Blood Pressure Insights marketed beyond clearance?
- On July 14 2025 the FDA issued Whoop a warning letter (MARCS-CMS 709755) stating that the Blood Pressure Insights (BPI) daily systolic/diastolic estimation feature on the WHOOP MG / Life membership is an unapproved medical device marketed without clearance, since BP estimation is inherently tied to diagnosis of hypo-/hypertension. Whoop publicly disagreed (Jul 15 2025) and BPI remained accessible; as of mid-2026 the dispute is UNRESOLVED with no recall. The load-bearing marketing-beyond-clearance exemplar of the biometric cohort.
- When did this incident occur?
- The incident is recorded as occurring on July 14, 2025 on the DEPLOY registry. The date reflects the underlying real-world event, not the registry record's creation date.
- What robot was involved in FDA warning letter to Whoop: Blood Pressure Insights marketed beyond clearance?
- Whoop (5.0 / MG) is the recorded robot involved in this incident.
- Has anyone responded to FDA warning letter to Whoop: Blood Pressure Insights marketed beyond clearance?
- No responses to this incident are recorded on the DEPLOY registry. Operators, manufacturers, or affected parties can submit responses to the editorial team; absence is not a guarantee no response was issued.
- What is the current status of FDA warning letter to Whoop: Blood Pressure Insights marketed beyond clearance?
- This incident is an active record on the DEPLOY registry; no retraction or correction has been issued.
Methodology: Verified · 2 sources (1 primary) · last reviewed 2026-06-04
Verification posture
Verified
High confidence
Review state
Stable
Last reviewed 2026-06-04
Sources by quality tier
- 1
- primary-fda-database
- FDA database
- 1
- unclassified
- Unclassified source
The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.
Methodology surface for FDA warning letter to Whoop: Blood Pressure Insights marketed beyond clearance.Canonical ID 2551f142-584e-48a5-978d-ff8c82023c01